Shionogi

PharmaShots Weekly Snapshots (September 27 – October 01, 2021)

BMS Reports EMA’s Validation of MAA for Relatlimab and Nivolumab as 1L Treatment for Unresectable or Metastatic Melanoma Published: Oct 1, 2021 | Tags: BMS, EMA, MAA, Relatlimab, Nivolumab, Metastatic Melanoma Merck and Ridgeback Report Interim Results of Molnupiravir in P-III MOVe-OUT Trial for the Treatment of COVID-19 Published: Oct 1, 2021 | Tags: Merck, …

PharmaShots Weekly Snapshots (September 27 – October 01, 2021) Read More »

ViiV Healthcare Signs an Exclusive License Agreement with Shionogi to Develop S-365598 for HIV

Shots: Shionogi to receive $27.2M up front, $20.4M upon the achievement of a clinical milestone along with royalties on net sales of S-365598 (HIV integrase inhibitor) & will provide the development costs up to an annual maximum The collaboration will advance ViiV Healthcare’s pipeline for HIV treatment. The therapy has the potential for use in …

ViiV Healthcare Signs an Exclusive License Agreement with Shionogi to Develop S-365598 for HIV Read More »

InveniAI Collaborates with Shionogi on AI-Based Drug Discovery

Shots: InveniAI is eligible to receive up to $200M/ program as up front, development, and commercial milestones along with royalties The collaboration integrates InveniAI’s AI platform AlphaMeld to identify, evaluate, optimize novel targets with Shionogi’s expertise in developing and commercializing therapeutic modalities Shionogi will synthesize targets identified by InveniAI for certain strategic diseases and will …

InveniAI Collaborates with Shionogi on AI-Based Drug Discovery Read More »

PharmaShots Weekly Snapshots (Jan 25- 29, 2021)

Roche Collaborate with Cambridge Quantum Computing to Develop Quantum Algorithm for Drug Discovery and Development Published: Jan 29, 2020 | Tags: Roche, Collaborate, Cambridge Quantum Computing, Develop, Quantum Algorithm, Drug, Discovery, Development Janssen Reports Results of Amivantamab in P-I CHRYSALIS Study for Metastatic or Unresectable NSCLC and EGFR Exon 20 Insertion Mutations Published: Jan 29, 2020 …

PharmaShots Weekly Snapshots (Jan 25- 29, 2021) Read More »

Shionogi Concludes a License Agreement with BioAge for BGE-175 to Control the Aggravation of COVID-19

Shots: Shionogi to receive an up front, milestones as well as royalties on sales of the therapy. BioAge to get exclusive US and EU rights to develop and commercialize BGE-17 for COVID-19 Additionally, BioAge gets an exclusive right to negotiate a license for additional indications and plans to initiate P-II study of BGE-175 for COVID-19 …

Shionogi Concludes a License Agreement with BioAge for BGE-175 to Control the Aggravation of COVID-19 Read More »

Tivicay approved in Europe in new dispersible tablet for children with HIV

ViiV’s Tivicay is to become available in Europe in a new dispersible tablet form to treat children living with HIV. The joint venture, majority-owned by GlaxoSmithKline with Pfizer and Shionogi as shareholders, said the European Commission had granted a marketing authorisation for the new formulation. These tablets are used in combination with other antiretroviral agents …

Tivicay approved in Europe in new dispersible tablet for children with HIV Read More »

PharmaShots Weekly Snapshot (Nov 30 – Dec 04, 2020)

Richter Acquires Janssen’s Evra Transdermal Contraceptive Patch Assets for $263.5M Published: Dec 3, 2020 | Tags: Asset Purchase Agreement, Evra, Gedeon Richter, Janssen Pharmaceutical, Signs, Transdermal Contraceptive Patch Assets, Treat Jazz Pharma and PharmaMar’s Zepzelca Fail to Meet its Primary Endpoint in P-III ATLANTIS Study for SCLC Published: Dec 3, 2020 | Tags: ATLANTIS, Doxorubicin, …

PharmaShots Weekly Snapshot (Nov 30 – Dec 04, 2020) Read More »

Shionogi and Nagasaki University Collaborate with the Kitasato Institute for Antimalarial Drugs

Shots: Kitasato & Shionogi-Nagasaki will collaborate on the R&D of the new antimalarial natural products discovered by Ōmura Satoshi Memorial Institute for the antimalarial drugs The collaboration accelerates the research for antimalarial drugs & vaccines by fostering an open innovation platform merging the strengths of diverse partners for malaria eradication Additionally, Shionogi-Nagasaki also collaborate with …

Shionogi and Nagasaki University Collaborate with the Kitasato Institute for Antimalarial Drugs Read More »

Shionogi Receives MHLW’s Approval for Xofluza’s sNDA to Treat Post-Exposure Prophylaxis of Influenza Virus Infection

Shots: The approval is based on P-III BLOCKSTONE study assessing Xofluza (baloxavir marboxil, 10/20mg) vs PBO in patients in household members aged ≥12yrs. who was living with someone with an influenza infection confirmed by a rapid influenza diagnostic test Result: The proportion of household members who developed influenza (1.9% vs 13.6%); well tolerated with no …

Shionogi Receives MHLW’s Approval for Xofluza’s sNDA to Treat Post-Exposure Prophylaxis of Influenza Virus Infection Read More »

ViiV’s twice-monthly injected PrEP drug superior in HIV prevention to Gilead daily pill, analysis shows

The company said Tuesday that a final analysis of its Phase IIb/III study of cabotegravir showed greater efficacy in HIV prevention than Gilead’s Truvada. The study, among men and transgender women who have sex with men, was stopped in May following an interim analysis.